Everolimus-Eluting Second-Generation Stents for Treatment of De Novo Lesions in Patients with Cardiac Allograft Vasculopathy.

CONCLUSIONS In the analyzed population, invasive strategy with second-generation everolimus-eluting stents for de novo lesions in cardiac allograft vasculopathy resulted in a low rate of binary restenosis, low late lumen loss, and no deaths during the 6-month follow-up.
PMID: 32253369 [PubMed - in process]

Source: Annals of Transplantation - April 6, 2020 Category: Transplant Surgery Authors: Pyka Ł, Hawranek M, Szyguła-Jurkiewicz B, Desperak P, Szczurek W, Lekston A, Gąsior M, Zembala MO, Pawlak S, Zembala M, Przybyłowski P Tags: Ann Transplant Source Type: research